Genmab ( (GMAB) ) just unveiled an update.
On March 12, 2025, Genmab A/S announced the constitution of its Board of Directors following its Annual General Meeting. Deirdre P. Connelly was appointed as Chair, and Pernille Erenbjerg as Deputy Chair. The company also granted 13,926 restricted stock units to board members and employees, and 4,214 warrants to employees, as part of its compensation program. These moves are expected to strengthen Genmab’s governance and incentivize its workforce, potentially enhancing its competitive positioning in the biotechnology industry.
More about Genmab
Genmab A/S is an international biotechnology company headquartered in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, Genmab has a proprietary pipeline that includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators. The company aims to transform the lives of people with cancer and other serious diseases through its advanced antibody medicines by 2030.
YTD Price Performance: -3.52%
Average Trading Volume: 1,469,787
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $12.84B
See more insights into GMAB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com